Meridian Life Science, Inc. (MLS) is investing $2.5M into facilities, equipment and infrastructure to support R&D and contract manufacturing activities. Increasing demand for contract R&D and biological reagent manufacturing has resulted in a comprehensive facilities plan that will allow MLS to meet customer needs and position the organization for further growth.

This facility expansion which started November 2010, follows the recent investment in 2009 of additional cleanroom biomanufacturing suites, a sterility suite and a pilot production laboratory.

These improvements provide additional capabilities for pilot scale and process development activities in support of cGMP biopharmaceutical manufacturing, which include cell and virus banking, live attenuated or recombinant viral vaccines, viral challenge materials, virus like particle vaccines, vectored gene therapy products, and recombinant proteins made in insect cell culture. The expansion will further enhance capabilities in upstream and downstream process development and optimization, scale-up, formulations, assay development, and viral quantitation. MLS continues to see strong interest in contract R&D, monoclonal antibody production, recombinant proteins, and Phase I/II clinical materials.

To discuss your contract manufacturing needs please contact Daniel A. Shelly, Ph.D., MBA, Director Business Development, 513272.5266 Dan.Shelly@MeridianLifeScience.com.

ABOUT MERIDIAN LIFE SCIENCE:

Meridian Life Science, Inc. provides contract R&D, process development, and manufacturing of critical assay reagents, antigens, antibodies, and contract biological R&D and manufacturing services.MLS also provides clinical cGMP biomanufacturing of vaccines, viral challenge materials, gene therapies, virus-like particles, and recombinant proteins. With 25 years of cell culture experience, protein expression, purification, assay development and quality, MLS has become a leader and trusted partner for the supply of critical reagents and clinical materials. MLS services its customers from three primary manufacturing operations in Memphis, Tennessee; Saco, Maine; and Boca Raton, Florida. The Company’s shares are traded through NASDAQ’s Global Select Market, symbol VIVO. Meridian’s website address is www.meridianlifescience.com.